Adaptimmune Annual report pursuant to Section 13 and 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 11,773	$ 18,240	$ 20,629
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	3,061	6,264	9,052
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 8,712	$ 11,976	$ 11,577